Form 4: Medline CEO Boyle Reports Significant Equity Holdings

Medline Inc. CEO James M. Boyle reported substantial acquisitions of Class B and Class A Common Stock, along with various incentive units, primarily linked to reclassification and RSU grants.

Summary

• James M. Boyle, Chief Executive Officer and Director of Medline Inc., reported transactions involving the acquisition of various equity and derivative securities.
• On December 16, 2025, Boyle acquired 24,313 shares of Class B Common Stock directly and 514,876 shares indirectly through a family trust.
• On December 16, 2025, Boyle also acquired 24,313 Common Units of Medline Holdings, LP indirectly and 514,876 Common Units indirectly through a family trust, which are exchangeable for Class A Common Stock on a one-for-one basis.
• On December 16, 2025, Boyle acquired a total of 4,182,759 Incentive Units of Medline Holdings, LP indirectly, with various participation thresholds ranging from $15.23 to $27.68.
• These Incentive Units are 'profit interests' convertible into Common Units, which are then exchangeable for Class A Common Stock.
• Vesting schedules for the Incentive Units vary, with some partially vested and others vesting in annual installments beginning in 2026.
• On March 5, 2026, Boyle received a grant of 31,739 shares of Class A Common Stock directly, representing Restricted Stock Units (RSUs).
• 25% of these RSUs vest on June 15, 2026, and the remaining 75% vest in three equal annual installments starting March 1, 2027.
• The acquisitions on December 16, 2025, were in connection with the reclassification of interests prior to Medline Inc.'s initial public offering and were previously reported on a Form 3 filed on December 17, 2025.
• All reported transactions were made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-slightly positive filing, primarily a disclosure of executive equity holdings and compensation structure following a reclassification event, which is a standard corporate action. The significant beneficial ownership aligns management interests with the company's long-term performance.

Positives

• The CEO's significant acquisition of equity and derivative securities demonstrates increased beneficial ownership, aligning management's interests with long-term shareholder value.
• The grant of Restricted Stock Units (RSUs) and various Incentive Units provides long-term incentives for the CEO, tied to the company's performance and equity value.
• The transactions were made pursuant to a Rule 10b5-1(c) plan, indicating pre-planned and structured equity management.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider filings like this Form 4 are routine disclosures for executives, particularly following significant corporate events such as an IPO or the implementation of new equity compensation plans. The structure of equity awards, including Class B shares, Common Units, and Incentive Units, reflects common practices in private equity-backed companies transitioning to public or quasi-public structures, designed to align management incentives with long-term shareholder value.

Comparison to Industry Standards

• StockSavvy.ai observes that the grant of restricted stock units (RSUs) and various tranches of incentive units with staggered vesting schedules is a standard compensation practice across industries, particularly in healthcare and medical supply sectors.
• Companies like Cardinal Health (CAH) and Owens & Minor (OMI), direct competitors in the medical distribution space, also utilize similar long-term incentive plans to retain key executives and incentivize performance.
• The specific vesting schedules and conversion mechanisms for incentive units are tailored to Medline's corporate structure, likely influenced by its recent reclassification prior to a potential IPO, which is a common feature seen in companies like DoorDash (DASH) or Airbnb (ABNB) during their public offerings, where pre-IPO equity structures are converted or reclassified.

Related Party Transactions

• 514,876 shares of Class B Common Stock and 1,057,309 Incentive Units are held indirectly by a family trust of which the Reporting Person's spouse is the trustee.

Stakeholder Impact

• Shareholders: Increased alignment of CEO's interests with shareholders through significant equity holdings and long-term incentive plans.
• Employees: The equity compensation structure, including RSUs and Incentive Units, is a common mechanism to incentivize key personnel.

Next Steps

• Vesting of 25% of granted RSUs on June 15, 2026.
• Remaining 75% of granted RSUs to vest in three equal annual installments beginning March 1, 2027.
• Remaining 38% of certain Incentive Units to vest on October 21, 2026.
• Remaining 60% of certain Incentive Units to vest in three equal annual installments beginning April 1, 2026.
• Remaining 60% of certain Incentive Units to vest in three equal annual installments beginning October 1, 2026.
• Remaining 80% of certain Incentive Units to vest in four equal annual installments beginning March 29, 2026.
• Certain Incentive Units to vest in five equal annual installments beginning March 28, 2026.

Key Dates

Recommendation

This Form 4 primarily details the CEO's equity holdings and compensation structure, including grants and reclassifications, rather than open market purchases or sales. While it shows significant insider ownership, which is generally positive for aligning interests, it doesn't provide new operational or financial performance data to warrant a change in investment thesis. The transactions are largely expected given the context of an IPO and executive compensation plans.

Keywords

Medline Inc., MDLN, Form 4, insider trading, beneficial ownership, CEO, equity acquisition, stock grant, RSU, incentive units, common stock, reclassification, IPO